Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy.

Rudolph, Abby E; Khan, Farid L; Shah, Amy; Singh, Tanya G; Wiemken, Timothy L; Puzniak, Laura A; Jodar, Luis; McLaughlin, John M

Rudolph, Abby E; Khan, Farid L; Shah, Amy; Singh, Tanya G; Wiemken, Timothy L; Puzniak, Laura A; Jodar, Luis; McLaughlin, John M.

Affiliation

Rudolph AE; Pfizer, Collegeville, Pennsylvania, USA.
Khan FL; Pfizer, Collegeville, Pennsylvania, USA.
Shah A; Walgreens Center for Health and Wellbeing Research, Deerfield, Illinois, USA.
Singh TG; Walgreens Center for Health and Wellbeing Research, Deerfield, Illinois, USA.
Wiemken TL; Pfizer, Collegeville, Pennsylvania, USA.
Puzniak LA; Pfizer, Collegeville, Pennsylvania, USA.
Jodar L; Pfizer, Collegeville, Pennsylvania, USA.
McLaughlin JM; Pfizer, Collegeville, Pennsylvania, USA.

J Infect Dis ; 229(3): 648-659, 2024 Mar 14.

Article in En | MEDLINE | ID: mdl-37925630

Subject(s)

COVID-19; Pharmacy; Humans; Adolescent; Adult; Child, Preschool; BNT162 Vaccine; mRNA Vaccines; COVID-19/epidemiology; COVID-19/prevention & control; SARS-CoV-2/genetics; Vaccines, Combined

Key words

BA.4/5; BNT162b2; COVID-19; Omicron; SARS-CoV-2; United States; VE; bivalent; effectiveness; test negative

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmacy / COVID-19 Limits: Adolescent / Adult / Child, preschool / Humans Language: En Journal: J Infect Dis Year: 2024 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google